Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Next Previous
X
Search
Trial Profile

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Albiglutide; Alogliptin; Dipeptidyl peptidase 4 inhibitors; Dulaglutide; Exenatide; Glucagon-like peptide-1 receptor agonists; Linagliptin; Liraglutide; Lixisenatide; Saxagliptin; Semaglutide; Sitagliptin
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMPRISE; EMPRISE United States
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 13 Jul 2023 Planned End Date changed from 30 Jun 2022 to 31 Dec 2024.
    • 13 Jul 2023 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2024.
    • 28 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top